**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 78701

**Manuscript Type:** MINIREVIEWS

**Management of liver diseases: Current perspectives**

Ray G. Management/liver diseases/current perspectives

Gautam Ray

**Gautam Ray,** Gastroenterology Unit, Department of Medicine, B.R.Singh (Railway) Hospital, Kolkata 700014, West Bengal, India

**Author contributions:** Ray G conceptualized the topic, collected data, drafted, edited and approved the final manuscript.

**Corresponding author: Gautam Ray, DNB, MD, Academic Research, Chief Doctor, Doctor, Teacher,** Gastroenterology Unit, Department of Medicine, B.R.Singh (Railway) Hospital, Parikshit Roy Lane, Near Sealdah Bus Stop, Beliaghata, Kolkata 700014, West Bengal, India. gautam1910@yahoo.com

**Received:** July 10, 2022

**Revised:** August 4, 2022

**Accepted:** September 21, 2022

**Published online:**

**Abstract**

There is increasing incidence and prevalence of acute and chronic liver diseases (CLDs) all over the world which influence the quality of life and can give rise to life threatening complications. The burden of advanced liver disease due to hepatitis B has been controlled by antivirals but its eradication is difficult. Highly effective directly acting antiviral therapy has reduced the burden of hepatitis C but is partially offset by increasing intravenous drug abuse. Non-alcoholic fatty liver disease is prevalent and there is recent alarming increase in alcohol-related liver diseases, for both of which no drug cure has been reported apart from control of the risk factors. Genetic factors have been identified in progression of all forms of CLD. Due to better management of complications of CLD, the life span of patients have increased spiking the number of hepatocellular carcinoma (HCC) and patients needing liver transplantation (LT). The present severe acute respiratory syndrome coronavirus (CODVID-19) pandemic has affected the outcome CLD including those with LT in addition to causing acute hepatitis. Better diagnostics and therapeutics are available for liver fibrosis, portal hypertension, HCC and post-LT management and many drugs are under trial. The present review summarizes the current scenario of the epidemiology and the advances in diagnosis and treatment of liver diseases including their complications such as portal hypertension, HCC and LT.

**Key Words:** Chronic liver disease; Genes; Biomarkers; Therapy; Hepatocellular carcinoma; Liver transplantation; Recent advances

Ray G. Management of liver diseases: Current perspectives. *World J Gastroenterol* 2022; In press

**Core Tip:** The incidence and prevalence of liver diseases is rising all over the world. Hepatitis B is difficult to eradicate and the benefit of directly acting antiviral therapy for hepatitis C is partially offset by increasing intravenous drug abuse. Non-alcoholic fatty liver disease is prevalent and alcohol-related liver disease is rising alarmingly, both having no drug cure. Due to better management of complications, patients of chronic liver disease are living longer spiking the number of hepatocellular carcinoma (HCC) and patients needing liver transplantation (LT). Better diagnostics and therapeutics are available for fibrosis, portal hypertension, HCC and post-LT management.

**INTRODUCTION**

Chronic liver disease (CLD) and cirrhosis pose substantial health burden worldwide. In the period 2007-2017, the age standardized prevalence increased by 10.4% with 1.5 billion cases in 2017[1]. Of the four chief etiologies of CLD, hepatitis B virus (HBV) and hepatitis C virus (HCV) burden still remains high [though decreased due to availability of vaccination for HBV and directly acting antiviral therapy (DAA) for HCV] and the non-alcoholic fatty liver disease (NAFLD) is prevalent and global alcohol consumption is increasing. NAFLD is the leading cause of CLD in developed nations, it is also becoming common in the developing nations like India, and China[2,3]. The age standardized prevalence of HBV/HCV related CLD rose by 9%/10.2% in the last decade whereas for NAFLD it was 23.5%[1]. The high HBV and HCV burden is mostly due to poor diagnostic coverage and linkage to treatment and care of the susceptible population.

**HBV**

The HBV pool is chiefly contributed to by the Western Pacific and Subsaharan Africa region (mostly tribals) and some southeast Asian countries (China, Vietnam, Thailand, Laos) where the load remains high despite the success of HBV vaccination program at birth. It is the leading cause of hepatocellular carcinoma (HCC) in these countries[4]. Among some developed and developing nations where HBV prevalence is intermediate to low, its burden is contributed by the indigenous tribal population such as in India and Australia[5,6] which maintained through intracaste marriages, close living, tribal customs, illiteracy and poor access to health care resources. With the present attrition rate (present burden of 296 million from 350 million 3 decades back and present annual mortality of 8 lakh and addition of 1.5 million cases in 2019[7]), it is still a long way for natural elimination of the pool. In the future, some redistribution is also likely due to population migration from high to low endemic regions. World Health Organization (WHO)’s ambitious program for eradication of HBV by 2030 therefore incorporates the best preventive measures, *i.e.*, increasing vaccination at birth, preventing vertical and horizontal transmission among toddlers by treating mothers at risk, and scaling up screening, care and treatment services. Curative treatment is difficult and < 20% patients who receive the currently approved drugs [interferon, nucleos(t)ide analog (NA) or combination as sequential/add-on/switch therapy] achieve loss of HBsAg (functional cure). Combination strategies are less cost effective than the first-line NA monotherapy although this may lead to more HBsAg loss in some subgroups of HBV patients[8]. Even with long-term NA monotherapy (Tenofovir disoproxil for 5 years), half fail to achieve fibrosis regression[9] and there is a high relapse rate in e negative patients (RETRACT B study showing a relapse rate of 47.8% at 6 mo, 68.9% at 12 mo, and 83.4% at 48 mo)[10]. The other problem is the risk of relapse in previously exposed person or inactive HBsAg carriers (who constitute a sizable majority of the present pool not requiring drug therapy) needing immunosuppression (IS) or cancer chemotherapy. Fortunately, highly active antivirals are capable of controlling the virus and reducing the burden of advanced liver disease caused by HBV. The chief impediments to HBV functional cure are intrahepatic viral reservoir cccDNA with integrated sequencing, high HBsAg levels, and defective host innate and adaptive immune responses. Newer strategies target these targeting HBV life cycle without damaging hepatocytes by inhibiting ccc DNA replenishment pathways or degrading them by entry inhibitors like Bulevirtide [used for HBV/HDV coinfection including post-liver transplantation (LT)], nucleic acid polymer assembly inhibitors (Lonafarnib), CRISPR/Cas9 protein base editors (DNA endonucleases), siRNAs, core protein modulators (Morphothiadin,Vebicorvir, Bersacapavir) and antisense oligonucleotide (Bepirovirsen)[2], and immunomodulation to safely eliminate infected cells. Potential targets in innate immune response pathway include pathogen recognition receptors [Toll-like receptors 7/8, retinoic acid-inducible gene (RIG)-1-like receptors and nucleotide-binding oligomerization domain (NOD)-like receptors], natural killer cells and antigen presenting cells (dendritic cells and Kupffer cells) whereas in adaptive immune response pathway, it includes modulation of HBV-specific CD4+ and CD8+ T cell (especially the relative functional and numerical deficiency of CD8+ T-cells by PD-1 checkpoint inhibitors), regulatory T cell, HBV-specific T and B cell (autologous, engineered or by vaccine).

**HCV**

Gratifying results have been obtained with the introduction of affordable short-term (3-6 mo) DAA therapy for HCV (with sustained viral response rates of > 95%, decreased fibrosis and HCC) with increasing treatment coverage in developed and developing nations which have decreased the HCV burden to 58 million as of 2019[7]. HCV still remains the leading cause of HCC in the developed world though alcohol related liver diseases (ALD)/NAFLD are fast taking the lead due to treatment with DAA. However, challenges still remain such as limited drug availability, interaction with other drugs used to treat comorbidities (HIV, coronary artery disease and hyperlipidemia), inability to afford even the low drug cost in patients without medical insurance and increasingly recognized metabolic dysfunctions associated with hepatitis C. Even in Denmark, 50% HCV patients are yet to attend specialist care especially intravenous drug users[11]. HIV coinfection is also a deterrent for good treatment outcome for both HBV and HCV. In future, the HCV pool is likely to be maintained by intravenous drug users and the increasing population with drug/alcohol abuse and other  psychiatric disorders, those needing repeated blood transfusion (for hematological disorders, hemodialysis) and reinfection in those who continue to have risk factors even after cure by DAA. WHO recommends increased access to treatment by onsite diagnosis using dried blood spot and initiating treatment at point of care and by trained non-specialist doctors and nurses.

**NAFLD**

NAFLD is the most common liver disease worldwide affecting about a quarter population with regional differences[12]. It is fast becoming the leading cause of cirrhosis in developed nations. Genetic inheritance (25%-34%), ancestry (HispanicAmerican/Asian/Indian > European > African American), advancing age and male sex are non-modifiable whereas obesity (especially central), diabetes mellitus, hyperlipidemia and insulin resistance are modifiable risk factors. There is currently no approved pharmacological therapy for NAFLD apart from those treating the risk factors. Weight loss through dietary alteration, physical exercises and bariatric surgery leads to improved liver histology but only a small percentage of patients can achieve and maintain the degree of weight loss needed for sustaining the benefit and 50% fail to improve histology[13]. Ursodeoxycholic acid (UDCA)/obeticholic acid (OCA), Vitamin E have no proven benefit. Therefore, it is the hottest area of newer drug research which modulate key metabolic, inflammatory, and fibrogenic pathway. Pan PPAR agonists (Lanifibranor), GLP 1 agonists (Semaglutide), CCR 5 inhibitors (Leronlimab), thyroid hormone receptor agonist (Resmetirom) and hepatic SCD1 inhibitor (Aramchol) are in phase 2 and 3 clinical trial (Table 1). Other antifibrotic and disease modifying agents as well as genetic factors are discussed below. Considering the multiple risk factors and complex pathophysiology, it is unlikely that a panacea will be discovered soon.

**ALCOHOL**

Approximately 2 billion people worldwide consume alcohol, of whom 283 million suffer from AUD[14]. ALD is most prevalent in the western world and in some affluent Asian countries (South Korea, Japan) though there is increasing global trend especially in newly industrialized southeast Asian nations (China, India, Vietnam, Thailand) where it was low due to traditional “dry” culture. ALD has become the leading cause of CLD/cirrhosis in India[5]. The recent coronavirus disease 2019 (COVID-19) pandemic has significantly increased the incidence of ALD in young adults. DALYs per 1000 people due to ALD was highest in India (2356.4), followed by the United States (467.9), China (466.3), Nigeria (424.5) and Indonesia (365.1). For alcohol-related liver cancer, DALYs were highest for China followed by Vietnam, Russia, Thailand, and India[15]. Consumption depends on age, sex, religion, culture, health status and national income distribution. Globally it is a tussle between national income from alcohol retail *vs* health expenditure for AUD, the latter being dismal even in developed nations. For this fully preventable disease, WHO proposes the most cost effective ways for prevention, *i.e.*, increasing taxation on alcoholic beverages, enforcing bans or comprehensive restrictions on exposure to alcohol advertising and restricting physical availability of retailed alcohol. A recent global study shows no safe dose for alcohol[16]. Abstinence can reverse fatty liver and halt the progression of CLD. It is responsible for 50% of deaths due to CLD because no specific drug therapy is available apart from some short-term benefit of steroids in pure acute hepatitis. Tumor necrosis factor alpha, growth hormone, pentoxyfylline and antioxidants at best show mixed results from highly variable to weak, and efficacy depending on the stage of disease. The unclear molecular mechanism of disease deter identifying treatment target and disincetivize drug development. Naltrexone, disulfiram and acamprosate help to decrease addiction. Obesity and cigarette smoking are known risk factors so weight control and quitting smoking are routinely encouraged. A poor overall nutritional status (protein calorie malnutrition, micronutrient deficiencies) often accompanies ALD and correlates positively with the development of serious complications hence a well-conceived nutrition support by oral, enteral, and parenteral routes is an essential part of standard care. Recent evidence also strongly implicates intestinal dysbiosis in ALD progression. These targets are being addressed by trials of probiotics, fecal microbiota transplantation, growth factors (granulocyte colony stimulating factor, bovine colostrum), antioxidants (w5 and synthetic fatty acids, S-adenosyl methionine + choline, N-Acetyl cysteine, vitamin C), in addition to liver regenerative biologics and device assisted behavioral alteration[17]. The other hindrances are disease stratification for early identification when it is most reversible, monitoring abstinence (as recidivism is high) and identifying risky drinking behavior like binges. Various biomarkers under study for this purpose include circulating small noncoding RNAs, long noncoding RNAs, selective cytokines profiles, phosphatidyl ethanol and urine ethyl glucuronide and ethyl sulphate[18-21].

**AUTOIMMUNE LIVER DISEASE**

Autoimmune hepatitis appears to be increasing in incidence as a part of the general increase in immune mediated and allergic diseases resulting from decreasing infectious diseases with mounting antibiotics use globally. Some antibiotics like nitrofuranotin, minocycline and coamoxyclav can induce autoimmune hepatitis by themselves and some antibiotic-associated drug induced liver disease (DILI) may resemble autoimmune hepatitis. The standard treatment of autoimmune hepatitis is steroids with/without azathioprine. Mycophenolate mofetil is a second-line drug. Substantial advances in treatment of autoimmune cholangiopathies has been achieved with PPAR α agonist bezafibrate, FXR agonist OCA and recombinant FGF 19, which alter bile acid synthesis along with antifibrogenic effect[22],and drugs inhibiting intestinal apical sodium-dependent bile acid transporter (linerixibat, maralixibat, odevixibat)[23], in addition to bile acid resins and UDCA. Combinations of such enterohepatic with cholehepatic and/or anti-fibrotic drugs could result in synergistic/additive effects in decreasing the fibrosis along with the pruritus.

**ADVANCES IN DIAGNOSIS**

Non-invasive biomarkers of CLD (patented ones such as fibrotest, fibrometer, Hepascore, ELF model and non-patented ones such as FIB 4 index, APRI, BARD, and NFS) and elastography (fibroscan, MRE, point SWE, 2D-SWE, 3D Velacur™) or their combinations (MEFIB, MAST, FAST) have been investigated across the whole spectrum of NAFLD to delineate the stage as well as correlating genes with liver fat, enzymes and fibrosis[24]. Novel ones like computed tomography (CT) scan with objective measures of liver nodularity and shunts, multiparametric magnetic resonance imaging (MRI) (iron corrected T1, cT1), extracellular vesicles, microbiome (stool microbial profiles), biomarkers for extracellular matrix remodeling (TGF-β, MMP, TIMP)[25-27] are being investigated. Graph convolution networks (a deep learning technique) are being tested for quantitative assessment of fibrosis[28].

**GENETIC FACTORS IN CLD**

Genetic factors are important in progression of all forms of CLD (ALD, NAFLD, metabolic-associated fatty liver disease, and chronic hepatitis) including HCC with interplay of genes involved in glucose, lipid and iron metabolism, insulin signaling, oxidative stress, inflammatory pathways and fibrogenesis. Most reliable fatty liver genes include *PNPLA3, TM6SF2, HSD17B13, GCKR and MBOAT7* (associated with increased liver fat, NASH, cirrhosis, HCC). The evidence for others like *MARC1, GPAM, APOE, ALDH1B, PCKS7, SERPINA1, HNF1A, etc*. is less robust. Rare variants like APOB and MTTP are associated with an increased risk of fat accumulation leading to HCC while protecting at the same time against dyslipidemia and cardiovascular risk[24]. Polygenetic risk scores (with/without clinical risk markers) are being investigated to stratify disease risk, *e.g.*, PNPLA3 and TM6SF2 can become a reason for HCC surveillance whilst giving protection from cardiovascular complications[29] It can also help in proper drug selection. Genetic therapies in CLD include gene silencing approaches (PNPLA3, HSD17B13), CRISPR/Cas9-based approaches[30], which alter responsible genes and modulating genes involved in liver regeneration.

**ACUTE HEPATITIS**

The etiology of acute liver failure (in those with normal liver) varies in different countries at different times. Most commonly these include viruses (hepatitis A, B and E), DILI (CAM, anti tuberculous drugs, paracetamol, anticonvulsants, antibiotics), toxins (herbs, alcohol) and autoimmune flares; these may precipitate acute liver failure in those with CLD (acute-on-chronic liver failure, ACLF). Hepatitis E virus may be associated with fulminant course in pregnancy. In tropical areas, malaria, dengue, enteric fever, leptospirosis and scrub typhus may also cause acute hepatitis. Traditionally Wilson disease and autoimmune hepatitis have been considered to cause acute liver failure, but in adults majority of such acute flares occur with underlying CLD. Most acute hepatitis of viral etiology recover by themselves and that of drug/toxin recover on their discontinuation, some DILI may need corticosteroid (especially those resembling autoimmune hepatitis). Bacterial infections respond to antibiotics. But the course of ACLF depends on the stage of the underlying CLD and the precipitating cause, and alcohol consumption which has the worst outcome[31,32]. Undefined acute hepatitis is occurring recently due to COVID-19 infection, recreational drugs and alcohol.

**PORTAL HYPERTENSION AND LIVER FIBROSIS**

With the increasing prevalence of CLD, portal hypertension and its complications are also increasing. Refractory ascites/hepatorenal syndrome/hydrothorax are now being better managed with terlipressin, noradrenaline, midodrine, octreotide and long-term albumin supplementation (with its newly discovered wider pleiotropic non-oncotic properties positively impacting decompensated CLD). Sodium-dependent glucose cotransporter 2 inhibitors and Alfa pump are under trial. Endohepatology (endoscopic ultrasound used in liver disease treatment)[33] has brought about dramatic improvement in the treatment of variceal bleeding by better delineation of collaterals and guided treatment (coiling, balloon retrograde transvenous occlusion of collaterals, glue injection in gastric varix), directed liver biopsy, portal pressure gradient measurement and  deployment of dedicated esophageal stents. Pre-emptive transjugular intrahepatic portasystemic shunt has been used for uncontrollable ascites or variceal bleed.

Fibrosis in the liver is caused by activated HSC whose biology connects damage, regeneration and cancer. Severe hepatic fibrosis represses regeneration and accumulation of senescent HSCs creates a pro-inflammatory, and pro-fibrotic environment. Fibrogenesis inhibitors resolve inflammation, cause loss of activated myofibroblasts, and ECM degradation Those under investigation (Table 1) include [FXR agonist OCA/cilofexor, acetyl-coenzyme A carboxylase inhibitor Firsocostat, ASK-1 inhibitor Selonsertib, CCR 2/5 inhibitor Cenicriviroc, FGF 19 analog Aldafermin/21 analogue Pegbelfermin, PPAR α/δ agonist Elafibranor, PPARγ agonist pioglitazone, PPAR α/γ agonist Saroglitazar, galectin 3 inhibitor Belapectin, CB1 antagonist Rimonabant, ECM production inhibitors like TIMP and MMP, lysyl oxidase 2 inhibitor Simtuzumab, HSP 47 inhibitor Pirfenidone, pan caspase inhibitor Emricasan and anti inflammatory lipids derivatives of PUFA (lipoxins, resolvins, protectins, and maresins)][34-36]. Statins have been found to have beneficial effect in halting the progress of CLD[37].

**HCC**

The main cause of HCC in the West is hepatitis C followed by NAFLD and alcohol whereas it is hepatitis B in Asia and Africa. Eighty percent occur in low and moderate resource countries. Screening program for HCC in cirrhotics is cost effective and better cancer surveillance can be achieved by the recently developed GALAD (incorporating AFP, AFP-L3, PIVKA, age and sex) screening tool[38] along with radiologic strategies (contrast-enhanced ultrasonography using Li-RADS, multiphasic CT/aMRI scan) every 6 mo in high-risk patients. Ninety percent HCCs occur with underlying CLD which pose additional health risk to HCC. Liver biopsy carries risk, hence liquid biopsy using detection of circulating tumor cells specific to HCC, mutation or methylation of circulating tumor DNA, and transcriptomic profiling of extracellular vesicles are promising. The widely followed BCLC staging system have been upgraded (to be more inclusive for surgery with/without downgrading of tumor) and provide better platform for optimal use of different treatment modalities like ablation, resection, LT, stereotactic body radiation, locoregional and systemic therapy. LT has been extended outside Milan criteria to include more patients by various expanded selection criteria with reduced but excellent long-term outcome[39]. Cancer in non-cirrhotic liver is treated by LT with better understanding of transplant oncology. Newer drugs like multikinase inhibitors (Lenvatinib, Regorafinib, Cabozantinib, Ramucirumab), checkpoint inhibitors (atezolizumab, bevacizumab, durvalumab, pembrolizumab, nivolumab, ipilimumab and tremelimumab) are now available over sorafenib for systemic therapy with better outcome[40]. Limitations are their unclear safety profile in Child-Pugh stage B, best response not more than 50%, unclear treatment sequence and use in early stage of tumor.

**LT**

ALD is now the predominant cause for LT followed by HCV and NAFLD in the West[41] whereas it is still HBV/HCV in the East with ALD at its heels[42]. With good patient selection, the present 1-year survival is 90% and 5-year 70%. Good outcome has been substantially influenced by improvement of surgical techniques, perioperative management, organ preservation (normothermic machine perfusion), recipient selection (through organ sharing network), post-transplant immunosuppressive management and diseases of viral etiology (DAA for HCV and Bulevirtide/NA for HBV/HDV). The challenge of limited organ availability has been addressed by accepting marginal and extended criteria donors (donors of cardiac death, 30%-60% steatotic liver explant without inflammation, HBsAg and HCV positive donors), split liver grafts and live donor transplant especially in Asia[41]. Liver regeneration-based approaches such as stem cell therapy and organ bioengineering can also help. Most post-transplant morbidity arise from prolonged use of immunosuppressives with resultant infections, hypertension, dyslipidemia, cardiovascular events, renal failure, malignancy and chronic organ rejection. Long-term outcome can be improved by minimizing/late introduction of standard IS or withdrawing it completely (20% become operationally tolerant) and using less toxic IS drugs (mToR inhibitors, interleukin 2 receptor blockers). With increased understanding of transplant immunology, research is underway whether IS can be completely withdrawn after finite treatment by modulating recipient immunity (by CD4 Treg cells, regulatory dendritic cells or hematopoietic stem cell transplantation)[43]. The problem of HCV relapse leading to cirrhosis in 30% has been addressed by DAA. Present challenges for liver transplant are: (1) High alcohol recidivism; (2) ACLF grade 3 and severe acute alcohol-related hepatitis; (3) NAFLD/non-alcoholic steatohepatitis with high comorbidities; (4) Frailty in advanced CLD; (5) Recipient and caregiver challenges; (6) Genetic variants; and (7) COVID-19. Severe acute respiratory syndrome coronavirus vaccine fails to decrease mortality as the patient's immunity is already weakened.

Artificial intelligence and digital transformation of various diagnostic modalities, decision-making tool and management will further advance the treatment of liver diseases.

**CONCLUSION**

The current scenario of the epidemiology and the advances in diagnosis and treatment of liver diseases including their complications are summarized in this review.

**REFERENCES**

1 **GBD 2017 Disease and Injury Incidence and Prevalence Collaborators**. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; **392**: 1789-1858 [PMID: 30496104 DOI: 10.1016/S0140-6736(18)32279-7]

2 **De A**, Duseja A. Nonalcoholic Fatty Liver Disease: Indian Perspective. *Clin Liver Dis (Hoboken)* 2021; **18**: 158-163 [PMID: 34691404 DOI: 10.1002/cld.1141]

3 **Xiao J**, Wang F, Wong NK, He J, Zhang R, Sun R, Xu Y, Liu Y, Li W, Koike K, He W, You H, Miao Y, Liu X, Meng M, Gao B, Wang H, Li C. Global liver disease burdens and research trends: Analysis from a Chinese perspective. *J Hepatol* 2019; **71**: 212-221 [PMID: 30871980 DOI: 10.1016/j.jhep.2019.03.004]

4 **World Health Organization**. WHO Global Hepatitis Report 2017. [cited 30 June 2022]. In: World Health Organization [Internet]. Available from: www.who.int/hepatitis/publications/global-hepatitis-report2017/en/

5 **Ray G**. Current Scenario of Hepatitis B and Its Treatment in India. *J Clin Transl Hepatol* 2017; **5**: 277-296 [PMID: 28936409 DOI: 10.14218/JCTH.2017.00024]

6 **Hanson J**, Fox M, Anderson A, Fox P, Webster K, Williams C, Nield B, Bagshaw R, Hempenstall A, Smith S, Solomon N, Boyd P. Chronic hepatitis B in remote, tropical Australia; successes and challenges. *PLoS One* 2020; **15**: e0238719 [PMID: 32881958 DOI: 10.1371/journal.pone.0238719]

7 **World Health Organization**. Hepatitis B and Hepatitis C. WHO bulletin 24 June 2022. [cited 30 June 2022]. In: World Health Organization [Internet]. Available from: www.who.in/Factsheets/Detail/Hepatitis

8 **Yin XR**, Liu ZH, Liu J, Liu YY, Xie L, Tao LB, Jia JD, Cui FQ, Zhuang GH, Hou JL. First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China. *Chin Med J (Engl)* 2019; **132**: 2315-2324 [PMID: 31567376 DOI: 10.1097/CM9.0000000000000445]

9 **Marcellin P**, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet* 2013; **381**: 468-475 [PMID: 23234725 DOI: 10.1016/S0140-6736(12)61425-1]

10 **Hirode G**, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, Papatheodoridi M, Lens S, Wong G, Brakenhoff SM, Chien RN, Feld J, Sonneveld MJ, Chan HLY, Forns X, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Hsu YC, Kao JH, Cornberg M, Hansen BE, Jeng WJ, Janssen HLA; RETRACT-B Study Group. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). *Gastroenterology* 2022; **162**: 757-771.e4 [PMID: 34762906 DOI: 10.1053/j.gastro.2021.11.002]

11 **Nielsen S**, Hansen JF, Hay G, Cowan S, Jepsen P, Omland LH, Krarup HB, Søholm J, Lazarus JV, Weis N, Øvrehus A, Christensen PB. Hepatitis C prevalence in Denmark in 2016-An updated estimate using multiple national registers. *PLoS One* 2020; **15**: e0238203 [PMID: 32881877 DOI: 10.1371/journal.pone.0238203]

12 **Cotter TG**, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. *Gastroenterology* 2020; **158**: 1851-1864 [PMID: 32061595 DOI: 10.1053/j.gastro.2020.01.052]

13 **Vilar-Gomez E**, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. *Gastroenterology* 2015; **149**: 367-78.e5; quiz e14-5 [PMID: 25865049 DOI: 10.1053/j.gastro.2015.04.005]

14 **World Health Organization**. Global status report on alcohol and health 2018. [cited 30 June 2022]. In: World Health Organization [Internet]. Available from: www.who.int/publications/overview/Global\_status\_report\_on\_alcohol\_and\_health\_2018

15 **World Health Organization**. Global health estimates 2016: Disease burden by cause, age, sex, by country and by region, 2000–2016. Global status report on alcohol and health 2018. [cited 30 June 2022]. In: World Health Organization [Internet]. Available from: www.who.int/data/Global\_Health\_Estimate

16 **Wood AM**, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, Paige E, Paul DS, Sweeting M, Burgess S, Bell S, Astle W, Stevens D, Koulman A, Selmer RM, Verschuren WMM, Sato S, Njølstad I, Woodward M, Salomaa V, Nordestgaard BG, Yeap BB, Fletcher A, Melander O, Kuller LH, Balkau B, Marmot M, Koenig W, Casiglia E, Cooper C, Arndt V, Franco OH, Wennberg P, Gallacher J, de la Cámara AG, Völzke H, Dahm CC, Dale CE, Bergmann MM, Crespo CJ, van der Schouw YT, Kaaks R, Simons LA, Lagiou P, Schoufour JD, Boer JMA, Key TJ, Rodriguez B, Moreno-Iribas C, Davidson KW, Taylor JO, Sacerdote C, Wallace RB, Quiros JR, Tumino R, Blazer DG 2nd, Linneberg A, Daimon M, Panico S, Howard B, Skeie G, Strandberg T, Weiderpass E, Nietert PJ, Psaty BM, Kromhout D, Salamanca-Fernandez E, Kiechl S, Krumholz HM, Grioni S, Palli D, Huerta JM, Price J, Sundström J, Arriola L, Arima H, Travis RC, Panagiotakos DB, Karakatsani A, Trichopoulou A, Kühn T, Grobbee DE, Barrett-Connor E, van Schoor N, Boeing H, Overvad K, Kauhanen J, Wareham N, Langenberg C, Forouhi N, Wennberg M, Després JP, Cushman M, Cooper JA, Rodriguez CJ, Sakurai M, Shaw JE, Knuiman M, Voortman T, Meisinger C, Tjønneland A, Brenner H, Palmieri L, Dallongeville J, Brunner EJ, Assmann G, Trevisan M, Gillum RF, Ford I, Sattar N, Lazo M, Thompson SG, Ferrari P, Leon DA, Smith GD, Peto R, Jackson R, Banks E, Di Angelantonio E, Danesh J; Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. *Lancet* 2018; **391**: 1513-1523 [PMID: 29676281 DOI: 10.1016/S0140-6736(18)30134-X]

17 **Xiao J**, Wang F, Wong NK, Lv Y, Liu Y, Zhong J, Chen S, Li W, Koike K, Liu X, Wang H. Epidemiological Realities of Alcoholic Liver Disease: Global Burden, Research Trends, and Therapeutic Promise. *Gene Expr* 2020; **20**: 105-118 [PMID: 32690129 DOI: 10.3727/105221620X15952664091823]

18 **Choudhuri S**. Small noncoding RNAs: biogenesis, function, and emerging significance in toxicology. *J Biochem Mol Toxicol* 2010; **24**: 195-216 [PMID: 20143452 DOI: 10.1002/jbt.20325]

19 **Han S**, Zhang T, Kusumanchi P, Huda N, Jiang Y, Yang Z, Liangpunsakul S. Long non-coding RNAs in liver diseases: Focusing on nonalcoholic fatty liver disease, alcohol-related liver disease, and cholestatic liver disease. *Clin Mol Hepatol* 2020; **26**: 705-714 [PMID: 33053941 DOI: 10.3350/cmh.2020.0166]

20 **Walsham NE**, Sherwood RA. Ethyl glucuronide and ethyl sulfate. *Adv Clin Chem* 2014; **67**: 47-71 [PMID: 25735859 DOI: 10.1016/bs.acc.2014.09.006]

21 **Gerbase FE**, Tegner M, Krutzmann ME, Muller VV, Alff JA, da Silva VB, Sagrilo OP, Linden R, Antunes MV. Blood phosphatidyl ethanol levels as a tool to detect alcohol misuse in trauma patients. *Clin Toxicol (Phila)* 2021; **59**: 418-425 [PMID: 33021410 DOI: 10.1080/15563650.2020.1822531]

22 **Gerussi A**, Lucà M, Cristoferi L, Ronca V, Mancuso C, Milani C, D'Amato D, O'Donnell SE, Carbone M, Invernizzi P. New Therapeutic Targets in Autoimmune Cholangiopathies. *Front Med (Lausanne)* 2020; **7**: 117 [PMID: 32318580 DOI: 10.3389/fmed.2020.00117]

23 **Al-Dury S**, Marschall HU. Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH. *Front Pharmacol* 2018; **9**: 931 [PMID: 30186169 DOI: 10.3389/fphar.2018.00931]

24 **Du X**, DeForest N, Majithia AR. Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities. *Front Endocrinol (Lausanne)* 2021; **12**: 777075 [PMID: 34950105 DOI: 10.3389/fendo.2021.777075]

25 **Nakao Y**, Amrollahi P, Parthasarathy G, Mauer AS, Sehrawat TS, Vanderboom P, Nair KS, Nakao K, Allen AM, Hu TY, Malhi H. Circulating extracellular vesicles are a biomarker for NAFLD resolution and response to weight loss surgery. *Nanomedicine* 2021; **36**: 102430 [PMID: 34174416 DOI: 10.1016/j.nano.2021.102430]

26 **Oh TG**, Kim SM, Caussy C, Fu T, Guo J, Bassirian S, Singh S, Madamba EV, Bettencourt R, Richards L, Yu RT, Atkins AR, Huan T, Brenner DA, Sirlin CB, Downes M, Evans RM, Loomba R. A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. *Cell Metab* 2020; **32**: 878-888.e6 [PMID: 32610095 DOI: 10.1016/j.cmet.2020.06.005]

27 **Yilmaz Y**, Eren F. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. *Eur J Gastroenterol Hepatol* 2019; **31**: 43-46 [PMID: 30134384 DOI: 10.1097/MEG.0000000000001240]

28 **Wojciechowska M**, Malacrino S, Martin NG, Fehri H, Rittscher J. Early detection of liver fibrosis using graph convolutional networks. Medical image computing and computer assisted intervention – MICCAI 2021: 24th International Conference, Strasbourg, France, September 27 – October 1, 2021, Proceedings, Part VIII, 2021: 217-226

29 **Jonas W**, Schürmann A. Genetic and epigenetic factors determining NAFLD risk. *Mol Metab* 2021; **50**: 101111 [PMID: 33160101 DOI: 10.1016/j.molmet.2020.101111]

30 **Alves-Bezerra M**, Furey N, Johnson CG, Bissig KD. Using CRISPR/Cas9 to model human liver disease. *JHEP Rep* 2019; **1**: 392-402 [PMID: 32039390 DOI: 10.1016/j.jhepr.2019.09.002]

31 **Gawande A**, Gupta GK, Gupta A, Wanjari SJ, Goel V, Rathore V, Bhardwaj H, Nijhawan S. Acute-on-Chronic Liver Failure: Etiology of Chronic and Acute Precipitating Factors and Their Effect on Mortality. *J Clin Exp Hepatol* 2019; **9**: 699-703 [PMID: 31889750 DOI: 10.1016/j.jceh.2019.04.050]

32 **Ray G**, Manjubhargav P. Clinical Presentation and Mortality Determinants of Alcohol-Related Liver Disease: A Single-Center Experience of the Rising Menace from Eastern India. *Inflamm Intest Dis* 2019; **4**: 104-114 [PMID: 31559262 DOI: 10.1159/000501274]

33 **Rudnick SR**, Conway JD, Russo MW. Current state of endohepatology: Diagnosis and treatment of portal hypertension and its complications with endoscopic ultrasound. *World J Hepatol* 2021; **13**: 887-895 [PMID: 34552695 DOI: 10.4254/wjh.v13.i8.887]

34 **Zhang J**, Liu Q, He J, Li Y. Novel Therapeutic Targets in Liver Fibrosis. *Front Mol Biosci* 2021; **8**: 766855 [PMID: 34805276 DOI: 10.3389/fmolb.2021.766855]

35 **Tan Z**, Sun H, Xue T, Gan C, Liu H, Xie Y, Yao Y, Ye T. Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy. *Front Cell Dev Biol* 2021; **9**: 730176 [PMID: 34621747 DOI: 10.3389/fcell.2021.730176]

36 **Maciejewska-Markiewicz D**, Stachowska E, Hawryłkowicz V, Stachowska L, Prowans P. The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD). *Biomolecules* 2021; **11** [PMID: 34202667 DOI: 10.3390/biom11070937]

37 **Bosch J**, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. *Gut* 2020; **69**: 953-962 [PMID: 32139553 DOI: 10.1136/gutjnl-2019-318237]

38 **Johnson PJ**, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, Morse J, Hull D, Patman G, Kagebayashi C, Hussain S, Graham J, Reeves H, Satomura S. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. *Cancer Epidemiol Biomarkers Prev* 2014; **23**: 144-153 [PMID: 24220911 DOI: 10.1158/1055-9965.EPI-13-0870]

39 **Yang JD**, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. *BMJ* 2020; **371**: m3544 [PMID: 33106289 DOI: 10.1136/bmj.m3544]

40 **Zhang H**, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. *Biomark Res* 2022; **10**: 3 [PMID: 35000616 DOI: 10.1186/s40364-021-00350-4]

41 **Burke NT**, Maurice JB, Nasralla D, Potts J, Westbrook R. Recent advances in liver transplantation. *Frontline Gastroenterol* 2022; **13**: 57-63 [PMID: 34970429 DOI: 10.1136/flgastro-2020-101425]

42 **Choudhary NS**, Bhangui P, Soin AS. Liver Transplant Outcomes in India. *Clin Liver Dis (Hoboken)* 2022; **19**: 32-35 [PMID: 35106148 DOI: 10.1002/cld.1166]

43 **Jadlowiec CC**, Taner T. Liver transplantation: Current status and challenges. *World J Gastroenterol* 2016; **22**: 4438-4445 [PMID: 27182155 DOI: 10.3748/wjg.v22.i18.4438]

**Footnotes**

**Conflict-of-interest statement:** The author reports no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** July 10, 2022

**First decision:** July 31, 2022

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Ji G, China; Rodrigues AT, Brazil **S-Editor:** Gao CC **L-Editor:** Ma JY-MedE **P-Editor:**

**Table 1 Interrim results of selective drug trials for non-alcoholic fatty liver disease and liver fibrosis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Agent** | **Mechanism** | **Phase** | **ClinicalTrials.gov number** | **Results** |
| Simtuzumab | Lysyl oxidase-like 2 monoclonal antibody | IIb | NCT01672879 | Ineffective in decreasing hepatic venous pressure gradient |
| Selonsertib | Selective inhibitor of apoptosis signal-regulating kinase 1 | III | NCT03053063 | Ineffective in improving fibrosis without worsening NASH |
| Emricasan | Pan-caspase inhibitor | II | NCT03205345 | No reduction in composite outcome of mortality and decompensation |
| Pegbelfermin | PEGylated fibroblast growth factor 21 analogue | IIa | NCT03486912 | Ineffective in improving fibrosis without worsening NASH |
| Lanifibranor | Pan peroxisome proliferator‑activated receptor agonists | III | NCT04849728 | Decrease of ≥ 2 points in the Steatosis Activity Fibrosis score without worsening of fibrosis in phase 2b trial |
| Resmetirom | Thyroid hormone receptor agonist | III | NCT03900429 | Significant reductions in liver fat content and serum atherogenic lipids in phase 2 trial |
| Aramchol | Hepatic stearoyl-CoA desaturase1 inhibitor | IIb | NCT02279524 | Insignificant decrease in liver triglycerides but significant improvement in liver inflammation and improvement of fibrosis ≥ 1 stage and serum ALT level |
| Leronlimab | Chemokine receptor 5 monoclonal antibody | II | NCT04521114 | Significant drops in liver fat, inflammation and fibrosis values as also in liver enzymes and multiple inflammation markers at week 14 compared to placebo |

NASH: Non-alcoholic steatohepatitis; ALT: Alanine transaminase.